Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Bio-Path Holdings, Inc.
Modality
nucleic_acid
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04196257CT.gov BP1001-A in Patients With Advanced or Recurrent Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peritoneum Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| bp1001-a (this asset) | Bio-Path Holdings, Inc. | P1 | CC · 41 |
| Cyclophosphamide | Peking University | P2 | BB |
| Docetaxel | University of Pittsburgh | P2 | BB |
| Fluorouracilum | City of Hope Medical Center | P3 | BB |
| Mirvetuximab Soravtansine | AbbVie | P3 | BB |
| Pembrolizumab | University College, London | P2 | BB |
| Carboplatin | Qilu Hospital of Shandong University | P3 | BB |
| Irinotecan | City of Hope Medical Center | P3 | BB |
| Rucaparib | pharmaand GmbH | P3 | BB |
+41 more in the Peritoneum Cancer cohort
Other indications for bp1001-a
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P1 | CC · 43 |
| Fallopian Tube Neoplasm | — | P1 | CC · 41 |
| Endometrial Carcinoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. bp1001-a in Peritoneum Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bp1001-a-peritoneum-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →